Regarding structural similarities to other known compounds, which statement is appropriate?

• A. They should be disclosed only in the patent filing
• B. Structural similarities to other known compounds should be mentioned
• C. They are confidential and must be hidden
• D. They should be described only in the marketing materials

Answer: (B)

Understanding how related compounds relate to a new investigational product is important for safety planning. If a compound shares structural similarities with other known compounds, that information can imply potential class effects, similar pharmacology, and comparable adverse events. Disclosing these similarities helps investigators anticipate risks, monitor for known safety signals, and assess how the new product might interact with other drugs. It also supports a thorough risk-benefit assessment, informs the informed consent process, and guides regulatory review and safety reporting.

Keeping such information hidden or limiting it to patent filings or marketing materials would withhold important safety and scientific context from investigators and regulators, which is not appropriate under GCP.